Investment Thesis
Amneal demonstrates solid operational performance with 8% revenue growth and positive free cash flow generation ($269.9M), but the negative stockholders' equity (-$70.8M) and high debt burden ($2.6B) create significant financial distress despite adequate liquidity. The company's thin net margin (2.4%) and weak return on assets (2.0%) suggest limited earnings power relative to its asset base and debt obligations.
AMRX Strengths
- Positive revenue growth of 8% YoY with $3.0B in total revenues
- Strong free cash flow generation of $269.9M with 8.9% FCF margin
- Adequate liquidity position with 2.17x current ratio and $282.0M in cash
- Improving diluted EPS (+157.9% YoY) indicating potential earnings leverage
AMRX Risks
- Negative stockholders' equity of -$70.8M indicates balance sheet insolvency risk
- High debt burden of $2.6B relative to net income and equity cushion
- Very low net profit margin of 2.4% limits financial flexibility and debt servicing capacity
- Operating leverage risk with thin margins vulnerable to revenue or cost disruptions
- Limited asset efficiency (2.0% ROA) raises questions about capital productivity
Key Metrics to Watch
- Debt reduction trajectory and leverage ratios (debt-to-EBITDA)
- Operating cash flow sustainability and free cash flow trend
- Gross and operating margin expansion or contraction
- Quarterly revenue growth consistency and product mix
- Equity recovery path and working capital efficiency
AMRX Financial Metrics
AMRX Profitability Ratios
AMRX Balance Sheet & Liquidity
AMRX 5-Year Financial Trend
5-Year Trend Summary: Amneal Pharmaceuticals, Inc.'s revenue has grown significantly by 44% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.48 indicates the company is currently unprofitable.
AMRX Growth Metrics (YoY)
AMRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $702.5M | -$156.0K | $0.00 |
| Q2 2025 | $701.8M | $6.0M | $0.02 |
| Q1 2025 | $659.2M | $12.2M | $0.04 |
| Q3 2024 | $620.0M | -$156.0K | $0.00 |
| Q2 2024 | $599.0M | $5.0M | $0.02 |
| Q1 2024 | $557.5M | -$6.9M | $-0.05 |
| Q3 2023 | $545.6M | -$7.6M | $-0.02 |
| Q2 2023 | $559.4M | $6.6M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AMRX Capital Allocation
AMRX SEC Filings
Access official SEC EDGAR filings for Amneal Pharmaceuticals, Inc. (CIK: 0001723128)